Ejigu Y, Magnus JH, Sundby J, et al. - Through a retrospective cohort study of 1,663 of pregnancies exposed to antiretroviral treatment (ART), researchers assessed pregnancy outcomes with regard to maternal ART regimens. Of these pregnancies, 17%, 19% and, 32% led to preterm birth, low birth weight, and a small-for-gestational-age baby, respectively. Zidovudine monotherapy was less prone to lead to preterm birth and low birth weight vs highly active antiretroviral therapy (HAART) started during pregnancy. When contrasting women who started HAART during pregnancy vs who initiated HAART prior to conception, no differential risk of preterm birth, low birth weight, and small-for-gestational-age was noted. In pregnant women taking nevirapine-based HAART, the risk for preterm birth was greater vs those taking efavirenz-based HAART. Among women who initiated HAART during pregnancy, a greater risk of preterm birth was seen vs zidovudine monotherapy. Pregnancies exposed to nevirapine-based HAART vs efavirenz-based HAART also had a higher risk of preterm births.